Core Viewpoint - Capricor Therapeutics Inc. is gaining attention in the biotechnology sector due to its investigational treatment, Deramiocel, for Duchenne muscular dystrophy (DMD) [1] Stock Performance - Alliance Global Partners upgraded Capricor's stock to a "Buy" rating, increasing the price target from $16 to $48, with the stock priced at $29.19 at the time of the upgrade [2] - The stock has surged 263% to $23.09 after achieving a key goal in a late-stage study for a cell therapy related to a heart condition associated with DMD [2] - The stock reached an intraday high of $40.37, marking its highest levels since 2017, and has gained 87.6% year-to-date, driven by a short squeeze with short interest increasing by 15% [3] Recent Developments - Capricor faced a setback earlier in the year when the FDA denied approval for Deramiocel, resulting in a 33% drop in stock value [4] - The company plans to resubmit Deramiocel for approval, supported by positive results from its Phase 3 HOPE-3 trial involving 106 participants, which has boosted investor confidence [4] - Currently, CAPR is priced at $29.19, reflecting a 359% increase with a change of $22.83, and has a market capitalization of approximately $1.33 billion with a trading volume of 42.14 million shares [5]